TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05889793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant takes a placebo for 10 consecutive days.
Study: NCT04976790
Drug: Flurbiprofen Cataplasms group (FCG).
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Flurbiprofen Cataplasm was applied to the left and right sides of the waist, twice daily, for 14 days
Study: NCT05274516
Drug: HRS-2261 tablet、placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-2261 oral tablet, oral, single dose. Matching placebo to HRS-2261, oral, single dose.
Study: NCT05274516
Drug: HRS-2261 tablet、placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-2261 oral tablet, oral, BID. Matching placebo to HRS-2261, oral, BID.
Study: NCT06400589
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same composition as tanfanercept but without the active ingredient
Study: NCT05034042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT05478512
Drug: VenObi+Ven or VenObi+VenZan
Normalized name: Apis mellifera ven protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive obinutuzumab 1000mg IV (cycle 1: day 1,8,15; Cycle2-6: day1) + venetoclax 400mg/d (preceded by a ramp-up phase) until cycle 9, day 28.~At cycle9:~* if uMRD = Venetoclax 400 mg/d orally until cycle 13.~* if residual disease in the BM or PB = Venetoclax 400 mg/d + Zanubrutinib 160 mg orally twice daily until cycle 21.~then, at cycle 21:~* if uMRD = stop treatment~* if residual disease in the BM or PB = zanubrutinib 160 mg orally twice daily until disease progression
Study: NCT06075134
Drug: Zinc Supplement
Normalized name: Zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: To increase efficacy of Botox
Study: NCT05294484
Drug: Indapamide 1.5 MG SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: the effect of genetic variation of UGT2B7 on human response to treatment with indapamide and its correlation with pharmacokinetic parameters in Egyptian subjects
Study: NCT06182098
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg/kg, with a maximum of 30mg
Study: NCT05653401
Drug: Magnesium sulfate and diclofenac
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 1 g of Magnesium Sulfate solution diluted in 10 ml of saline solution administered over 2 to 4 minutes
Study: NCT05653401
Drug: Lidocain and diclofenac
Normalized name: diclofenac / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 10 ml of Lidocaine 1% solution administered over 2 to 4 minutes.
Study: NCT05653401
Drug: Placebo and diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 75 mg of Diclofenac solution and 10 ml Intravenous injection of serum saline ( as a Placebo Comparator ) administered over 2 to 4 minutes.
Study: NCT05034809
Drug: Melatonin 20 MG
Normalized name: melatonin 20 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin, also known as N-acetyl-5-methoxytryptamine will be the main intervention given to participating patients of this study. This study will use a dose of 20mg/day using the commercially available 5mg/tablet20-21. If a patient cannot be tolerate swallowing the whole tablet, it will be crushed and mixed with milk. According to the study done by Shah et al. there was no degradation in the active component of melatonin when mixed with milk or food as a medium for drug delivery.
Study: NCT05257590
Drug: CVM-1118
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.
Study: NCT05754411
Drug: [14C]STI-1558
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting oral administration of 600 mg \[ 14C \] STI-1558 ( about 100 μCi ) solution.
Study: NCT00001059
Drug: Doxorubicin hydrochloride (liposomal)
Normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06093542
Drug: AZD7053
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised participants will receive AZD7503 subcutaneously.
Study: NCT06093542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised participants will receive placebo subcutaneously.
Study: NCT05084079
Drug: CSII with formula-based initial insulin regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial total daily insulin dose(TDD) for CSII was calculated with a formula :（estimate TDD-1(eTDD-1) = 0.35× body weight (kg) + 2.05× FPG (mmol/L) + 4.24×triglyceride(mmol/L) + 0.55× waist circumference (cm) - 49.1）, 42% of which was assigned as total basal dose and 58% as total premeal dose, with the pre-meal doses divided into 30:35:35 for breakfast, lunch and dinner.
Study: NCT05084079
Drug: CSII with weight-based initial insulin regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDD for CSII was started with 0.5 IU/kg, 50% of which was assigned as total basal dose and 50% as total premeal dose, and the total pre-meal dose was divided equally before each meal.
Study: NCT00001033
Drug: Pyridoxine hydrochloride
Normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05871424
Drug: placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: simple dressing tape only will be applied
Study: NCT05466643
Drug: DWP16001 0.3mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, Orally, Once daily single dose
Study: NCT05466643
Drug: DWP16001 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, Orally, Once daily single dose
Study: NCT05497739
Drug: Adjuvant systemic chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m\^2 on Day 1; S-1 depends on Body Surface Area (BSA), 40 mg Bid, Days 1-10 (BSA \< 1.25 m\^2), 50 mg Bid, Days 1-10 (BSA 1.25-1.50 m\^2), 60 mg Bid, Days 1-10 (BSA \> 1.50 m\^2).
Study: NCT06315972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: add-on placebo + aerobic exercise training
Study: NCT04923594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed orally, once daily for up to 4 weeks.
Study: NCT06549504
Drug: AG2202T
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG2202T Single-dose
Study: NCT06549504
Drug: AG2202R
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG2202R Single-dose
Study: NCT05667883
Drug: glucocorticoid + cytoxan
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d; Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.
Study: NCT03451487
Drug: Panadol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500mg Tablet
Study: NCT03451487
Drug: SafeTynadol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500mg Tablet
Study: NCT06190470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is similar to Cannabis product but do not contain THC.
Study: NCT05210088
Drug: Hypoxia, intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored.
Study: NCT03654040
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care.
Study: NCT06314906
Drug: Antiemetic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral olanzapine at a dose of 5 mg per day on days 1 through 4, along with NK1 receptor antagonist, 5HT3 receptor antagonist, and intravenous dexamethasone at a dose of 10 mg 30 minutes prior to chemotherapy on Day 1, followed by intravenous dexamethasone at a dose of 8 mg on days 2, 3, and 4 post-chemotherapy.
Study: NCT04907825
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with ACC/AHA/HRS Guidelines
Study: NCT06200597
Drug: LAD603
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAD603 SC injection.
Study: NCT06314906
Drug: Antiemetic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: They will also receive the same antiemetic medications as the experimental group.
Study: NCT05424835
Drug: Pyrotinib in combination with Capecitabine.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib in combination with Capecitabine.
Study: NCT05820841
Drug: R-miniCHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5).~Cycles repeated every 3 weeks
Study: NCT05111197
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy continue their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.
Study: NCT05209620
Drug: ICP-022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration (3 weeks/cycle, total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle).
Study: NCT06215820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: over-encapsulated tablet and/or tablet
Study: NCT06216041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort).
Study: NCT06216041
Drug: Placebo ( FE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods.
Study: NCT06107374
Drug: [18F]F-AraG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two PET scans
Study: NCT06448130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo+ lifestyle intervention
Study: NCT04764097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00930995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT04625101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active dosage form.
Study: NCT05824663
Drug: HBM1020
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Administrations on Days 1 of each 21-day treatment cycle.
Study: NCT06228482
Drug: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
Study: NCT06297174
Drug: HIDRASEC®
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIDRASEC® (reference drug)
Study: NCT06176781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Simulants(Edaravone Dexborneol concentrated solution for injections) administered intravenously for 5 - 10 days, and then followed by Sublingual Tablet Simulants(Edaravone Dexborneol Sublingual Tablets) BID administered sublingually for the last days, the total duration of treatment was 14 days
Study: NCT05447520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet once daily
Study: NCT05447520
Drug: Conventional DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
Study: NCT06391008
Drug: Evoximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evoximab (20mg/kg, Q3W)
Study: NCT06125184
Drug: Vasopressor test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean arterial pressure will be increased from 65 mmHg to 85 mmHg to improve organ perfusion pressure.
Study: NCT04733651
Drug: Hospital standard of care for COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care for COVID-19 as per the hospital guidelines
Study: NCT05729555
Drug: Compound ibuprofen polyrelease tablets
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
Study: NCT05729555
Drug: reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃ manufacturer: JOHNSON \& JOHNSON CONSUMER INC. Usage and dosage：Once a day, two tablets at a time~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading manufacturer: JOHNSON \& JOHNSON CONSUMER INC Usage and dosage：Once a day, two tablets at a time
Study: NCT06219915
Drug: Carbidopa-Levodopa 25/100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
Study: NCT06219915
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take one 25mg placebo tablet 3 times a day for 10 days.
Study: NCT06219915
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take one 100mg placebo tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
Study: NCT05082766
Drug: enhanced DefenAge 8-in-1 BioSerum
Approvals — FDA: no, EMA: no, PMDA: no
Description: DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.
Study: NCT02016495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06374888
Drug: Neratinib maleate in combination with capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib maleate tablets，Tablets, 40mg/ tablet, 180 tablets/bottle, orally, 240mg once daily, sealed, stored not above 25℃
Study: NCT04871828
Drug: Leukotriene Receptor Antagonist
Normalized name: Leukotriene receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast
Study: NCT05363722
Drug: IBI310（0.5mg/kg）
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI310 0.5mg/kg IV d1 Q6W
Study: NCT05363722
Drug: IBI310（0.3mg/kg）
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI310 0.3mg/kg IV d1 Q6W
Study: NCT04853342
Drug: Drug: Furmonertinib 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of Furmonertinib 80 mg once daily
Study: NCT04853342
Drug: Furmonertinib 80 mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of Furmonertinib 80 mg once daily
Study: NCT06284226
Drug: Allogeneic NK（CCT-ANK-11)
Approvals — FDA: no, EMA: no, PMDA: no
Description: allogeneic natural killer cells
Study: NCT05538949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1Drop, QD / Day1, BID / Day5\~Day8.
Study: NCT05537571
Drug: SLN360
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)
Study: NCT05537571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride, solution for injection
Study: NCT05862974
Drug: LPM3480392
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 30min duration
Study: NCT05862974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 30min duration
Study: NCT05023811
Drug: [14C]RIST4271
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]RIST4271 oral solution
Study: NCT05300490
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this routine care study, all patients will receive a joint injection of prednisolone at a dose left to the discretion of the physician. The urinary excretion kinetics of this product and its metabolites will then be followed at different times. An association with metabolic genetic profile will be done.
Study: NCT06429501
Drug: Bupivacaine/Epinephrine
Normalized name: BUPIVACAINE/EPINEPHRINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection
Study: NCT04742673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.
Study: NCT05798572
Drug: Sildosin group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group had flexible ureteroscopy (F-URS) with preoperative daily uptake of 8 mg silodosin for one week.
Study: NCT05094934
Drug: NNC0385-0434 A 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.
Study: NCT04968899
Drug: Neofordex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21.
Study: NCT04968899
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (1g/kg D1-D2) plus oral prednisone (1 mg/kg/day x 21 days (3 weeks))
Study: NCT05911360
Drug: DTG/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG/3TC FDC will be administered once daily.
Study: NCT04884217
Drug: Pro-ocular™ Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro-ocular™ Topical Gel 1% is applied dermally to the forehead twice-daily
Study: NCT04884217
Drug: Placebo Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a toopical gel without active ingredient applied dermally to the forehead twice-daily
Study: NCT06377397
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: In experimental arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered selectively to those newborn infants who later develop clinical signs of sepsis according to a predefined repertory of clinical signs.~In active comparator arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered pre-emptively to all newborn infants from enrollment even if they do not have any clinical signs of sepsis at enrollment
Study: NCT03595150
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac rectally given before the ERCP to prevent pancreatitis
Study: NCT06102512
Drug: [¹⁴C]-LOXO-783
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06102512
Drug: [¹⁴C]-LOXO-783
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06442566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: double-blinded randomization to placebo or transdermal buprenorphine
Study: NCT06289894
Drug: BRY805 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRY805 will be administered via IV infusion every 3 weeks. , Six dose levels of 0.3, 1, 3, 9,18 and 30 mg/kg will be tested
Study: NCT05656222
Drug: VIA combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: a 90-minute intravenous infusion of irinotecan at a dose of 50 mg/m2/d for 5 days every 3 weeks, vincristine given at a dose of 1.4 mg/m2 (maximum 2 mg) on days 1 and 8, and oral administration of Anlotinib once daily on days 1-14 within a 21-day cycle.
Study: NCT05132179
Drug: Dakins Full Strength Solution, 0.5% Topical Solution, HOCl solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dakin´s solution is a 50/50 mixture of 1% sodiumhypochlorite and 2% sodiumhydrocarbonate, the mixture is a 0,5% chlorine solution. Dakin´s solution is not used in Sweden on wound. Dakin´s solution is only used in dental care in Sweden.
Study: NCT05603559
Drug: 1.1 GBq (30 mCi) of 177Lu-P17-087
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-087 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.